MINNEAPOLIS, June 9 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today noted that several key opinion leaders will be reporting their experience with ATS Medical products and related procedures during the scientific program of the upcoming International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) annual meeting in Boston.
On Wednesday, June 11th, Dr. James Cox, ATS Medical Director, will present the "History of Arrhythmia Surgery: Lessons Learned from Surgical Extinction". The ATS CryoMaze(TM) Surgical Ablation System is proven to yield clinical results similar to the conventional cut-and-sew Cox Maze III procedure for the surgical ablation of atrial fibrillation and will be the focus of several additional scientific presentations. On June 11th, Dr. Evilio Rodriguez of East Carolina Medical Center will present the "Cryo-Maze Procedure." On Friday, June 13th, Dr. Harold Roberts of Florida Medical Center will present his unique procedure the "Robotic Endoscopic Cox-Cryomaze: A Minimally Invasive Cure of Continuous Atrial Fibrillation." Dr. Roberts will expand on the clinical benefits of the ATS CryoMaze procedure in a poster session titled "Short-Term Outcomes Confirm the Effectiveness and Safety of Cryomaze in Patients Undergoing Concomitant Cardiac Surgeries." These presentations speak to the expansion of cryoablation into minimal access and stand-alone surgical procedures for the treatment of atrial fibrillation that can improve efficacy while reducing the risk profile.
The ATS 3f Enable(R) Aortic Bioprosthesis is currently in clinical trials in Europe and is designed to eliminate the traditional suturing now required when replacing a patient's diseased or degenerated aortic heart valve. On Thursday, June 12th, Professor Thierry Carrel, from Bern, Switzerland, will present "Sutureless Valves: Design, Implantation Technique and Early Clinical Result" and Professor Sven Martens, from Frankfurt, Germany will present "Single Center Experience with the ATS Enable Bioprosthesis." Both will demonstrate the excellent early clinical outcomes with regard to both implantation and valve performance.
Michael D. Dale, Chairman, President and CEO of ATS Medical noted, "We are very gratified that ATS Medical products will be the focus of a variety of key presentations at this year's ISMICS meeting. It illustrates that our strategic plan to expand into bioprostheses, cryotherapy and minimally invasive approaches has well positioned us in technologies that are innovative, forward thinking and of great interest to cardiac surgeons. ATS Medical continues to gain recognition as a prominent entity in these market segments and we look forward to introducing product innovations that allow surgeons to advance the standard of care for their patients."
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The Company, global in scope, is headquartered in Minneapolis, Minnesota. More than 145,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.
This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2007 and its most recent quarterly report on Form 10-Q.
|SOURCE ATS Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved